Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

PUBLISHED: 21 September 2018
PAGES: 135
PRODUCT CODE: PHA0332
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0332 Categories: , Tags: , ,

The global acute myeloid leukaemia market reached $1bn in 2017 and is estimated to reach $2.8bn by 2022. In 2017, the chemotherapy segment held 69% of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 135-page report you will receive 92 charts– all unavailable elsewhere.

The 135-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Acute Myeloid Leukaemia Market from 2018-2028

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2028 for these regional and national markets:
North America: US, Canada, and Mexico
Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA

Global Acute Myeloid Leukaemia Market Forecast 2018-2028

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Buy our report today Global Acute Myeloid Leukaemia Market Forecast 2018-2028: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast 2018-2028


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category